CAR T cell therapy in type 1 diabetes: what we know and what remains to be explored Authors: Sandesh Kumar Pattanaik, Diptirani Rath, Amir Mansour Moeini, Mohsen Nabi Afjadi Published: 2025 ABSTRACT With its increasing prevalence, diabetes continues to be a major global health concern. Insulin resistance and elevated blood glucose levels are the results of type 1 diabetes (T1D), an autoimmune disease that destroys pancreatic β cells. The underlying immune-mediated harm cannot be prevented or reversed despite a variety of therapy approaches. Recent advancements in immunotherapy are positioned as a viable option for treating T1D. A genetically modified T cell that recognizes and destroys disease-specific targets is used in chimeric antigen receptor (CAR) T-cell therapy. Its targeting of the CD19 and BCMA antigens led to a breakthrough in hematologic malignancies. The present knowledge of CAR-T treatment in T1D is expanded upon by this review. However, there are still a number of important obstacles that limit clinical application, including safety, effectiveness, and technological problems. The main achievements of CAR-T cell treatment for T1D will be discussed in this paper, along with the present challenges and potential future paths for customized CAR-T cell therapies. By combining existing knowledge with uncharted territory, this review aims to stimulate more research and innovation in the field, perhaps leading to a paradigm shift in the treatment of diabetes. Introduction As the first line of protection against illnesses and infections, the immune system plays the role of a watchful guardian. Through antigen-specific receptors, T cells identify and destroy diseased or aberrant cells, playing a crucial function among its constituents. However, this defensive system is compromised because cancer cells have developed complex strategies to avoid immune identification and killing [1]. A new strategy known as chimeric antigen receptor T cell (CAR-T) therapy has surfaced to combat this immune evasion. In this treatment, patients' own T cells are genetically modified to carry synthetic receptors that allow them to more efficiently identify and combat cancer cells [2]. Mechanistically, CAR-T cells are created by fusing internal T cell signaling domains like CD3ζ and costimulatory molecules (e.g., CD28, 4-1BB) with an extracellular antigen-binding domain, which is typically obtained from a single-chain variable fragment (scFv) of an antibody. Bypassing the need for major histocompatibility complex (MHC)-restricted antigen presentation, this modified receptor enables CAR-T cells to very specifically detect tumor-associated antigens directly. Through proliferation, cytokine production (such as TNF-α and IFN-γ), and the release of cytolytic granules, CAR-T cells effectively lyse tumor cells when they come into contact with their target antigen. The creation of second- and third-generation CARs with numerous costimulatory domains and safety switches to reduce side effects is one example of how advancements in CAR design have further improved persistence, effectiveness, and safety [3, 4]. In hematologic cancers, including B-cell lymphomas and acute lymphoblastic leukemia, CAR-T therapy has demonstrated exceptional efficacy, producing long-lasting remissions when traditional treatments frequently fall short. This achievement has sparked research into CAR-T cell uses outside of cancer, such as in autoimmune disorders [3, 4]. The hallmark of T1D is the death of pancreatic β-cells by autoreactive T lymphocytes, which results in a complete lack of insulin and ensuing hyperglycemia. After infiltrating islets, autoreactive CD8 + cytotoxic T lymphocytes cause β-cell death and the generation of inflammatory cytokines. The primary goal of current treatments is insulin replacement; the underlying immunological dysregulation is not addressed [5]. In this regard, CAR-T treatment is being modified to improve the suppressive function of regulatory T cells (Tregs) or to selectively target and eradicate pathogenic autoreactive T cells in order to restore immunological tolerance. Recent preclinical research has shown that in T1D models, CAR-T cells that are designed to identify autoreactive T cell receptors or disease-specific antigens can maintain β-cell function and lessen autoimmune reactions. These results imply that CAR-T treatment may offer long-lasting, antigen-specific immunomodulation, which might stop or reverse the course of T1D [6]. With an anticipated 537 million people globally suffering from diabetes mellitus in 2021 and that number expected to rise to 643 million by 2030, the condition continues to be a major global health concern. Despite making up about 5–10% of all instances of diabetes, T1D disproportionately affects children and young people and has no known cure [7]. CAR-T cell therapy is a potential targeted immunotherapeutic approach that might revolutionize T1D management by reestablishing immunological homeostasis, especially considering the limits of traditional therapies in avoiding immune-mediated β-cell death [6, 8]. This review presents the current summary of the mechanisms behind CAR-T cell therapy, outlines the latest advancements in its use for T1D, the issues and safety concerns, and the future research avenues that are essential to successfully bringing this innovative treatment from the bench to the bedside. Biology of CAR-T therapy History The concept of chimeric T-cell receptors (cTCRs) first emerged in 1987, pioneered by Dr. Yoshikazu Kurosawa and his team in Japan. Their groundbreaking work proved that combining antibody-derived variable regions (VH/VL) with T-cell receptor (TCR) constant regions could enable T cells to recognize and respond to antigens. This discovery set the stage for future developments in immunotherapy [9]. Dr. Zelig Eshhar and his colleagues, in 1989, at the Weizmann institute of science improved upon the method by designing chimeric TCRs that are independent of major histocompatibility complex (MHC) expression. Through a combination of antibody-derived variable chains and TCR constant regions, they generated effective receptors for antigen recognition, activating T-cells and producing cytokines. The first cTCR design still needed two individual viral vectors, which compromised on efficiency. Dr. Eshhar's lab developed the single-chain variable fragment receptor (scFvR) that preceded modern CARs in order to overcome this constraint, therefore allowing simpler transduction and different T cell activation [10]. During the 1990 s, animal research refined the idea. The University of Pennsylvania, in partnership with the Children's Hospital of Philadelphia, brought the first CAR-T therapy from the laboratory to the clinic. Under the direction of Dr. Carl June, researchers overcome key challenges in cell engineering persistence and safety [11]. 2011 was a turning point when CAR-T cells were administered to patients suffering with chronic lymphocytic leukemia [12]. Later that year, a seven-year-old child with acute lymphoblastic leukemia (ALL) received the treatment. Regardless of having serious side effects, the patient's condition got better, proving the life-saving power of CAR-T therapy and giving the field new impetus [13]. Structure of chimeric antigen receptors T cells (CAR-T) Four major subunits of CARS: (1) a target antigen-binding extracellular moiety, (2) a hinge, (3) a transmembrane segment, and (4) one or more intracellular signal domains (Fig. 1). The upcoming section summarizes CAR design concepts [14].Fig. 1The figure presents a comprehensive overview of CAR-T cells. It includes the antigen-binding domain (scFv), hinge region, transmembrane domain, and intracellular signalling domains [15] The figure presents a comprehensive overview of CAR-T cells. It includes the antigen-binding domain (scFv), hinge region, transmembrane domain, and intracellular signalling domains [15] The extracellular target antigen-binding domain is responsible for recognizing and binding to target antigens on the surface of tumor cells. It is typically composed of a single-chain variable fragment (scFv) of monoclonal antibody variable heavy (VH) and light (VL) chains. The domain is responsible for high specificity and makes CAR-T cells capable of recognizing tumor cells irrespective of major histocompatibility complex (MHC) presentation [16]. The hinge region links the antigen-binding domain and the transmembrane domain and provides flexibility to enable proper positioning of the receptor for antigen binding. The structure and length of the hinge region are accountable for CAR-T cell function, regulation of receptor expression, signal efficiency, accessibility of the epitope, and general activation amplitude. It is normally derived from IgG1/IgG4, CD28, and CD8 proteins [17]. The transmembrane domain stabilizes receptor expression and tethers CAR to the T-cell membrane and also contributes to intracellular signalling and immune synapse formation. It is cloned most frequently from transmembrane proteins like CD3ζ, CD8α, or CD28 that modulate the efficacy of receptor signalling and CAR's overall function. The CD3ζ transmembrane portion facilitates CAR-induced T-cell activation through dimerization of the receptor and incorporation into native TCR complexes. CD28 and CD8α transmembrane parts enable increased receptor expression and stability and are therefore popular for use in CAR-T constructions [18, 19]. The intracellular signalling domains mediate activation of the T-cell when antigens are recognized. CD3ζ is the main signalling domain that initiates T-cell activation. Other costimulatory domains, including CD28, 4-1BB, OX40, MYD88/CD40, and ICOS augment T-cell expansion, survival, and cytotoxic function. The intracellular components control the magnitude and persistence of the CAR-T cell response to cancer cells [20]. Generation of chimeric antigen receptor T cells With rising efficacy and safety, the history of CAR-T cell treatment has seen an evolutionary change in the past few years. CAR-T cell design has been classified into five generations, each enhancing the previous one to enhance its utility and therapeutic uses (Fig. 2).Fig. 2Evolution of CAR-T cell generations across five generations. In the 1 st generation, there is no second co-stimulation domain, whereas Mordan CAR-T cells (2nd –5th generation) include co-stimulatory domains Evolution of CAR-T cell generations across five generations. In the 1 st generation, there is no second co-stimulation domain, whereas Mordan CAR-T cells (2nd –5th generation) include co-stimulatory domains In the late 1990 s and 1980 s, the 1 st generation of CAR-T cells was designed, in which an scFv from an antibody was fused with a CD3ζ signalling domain. These cells could recognize target antigens and initiate some degree of activation [20]. Due to insufficient costimulatory signals, their persistence and cytotoxic effectiveness were limited. To improve persistence and more prolonged cytotoxic effects, CAR-T cells in the 2nd generation incorporated an additional costimulatory domain, such as 4-1BB or CD28, along with CD3ζ [21]. The addition profoundly promoted the longer-lasting killing effects on cancer cells. To continue this, the 3rd generation CAR-T cells further improved upon this design by incorporating two costimulatory domains, i.e., CD28 and 4-1BB or CD28 and OX40, to achieve greater proliferation, persistence, and longer-lasting killing effects via producing many cytokines [22]. The 4th generation, or "T cell Redirected for Universal Cytokine-mediated Killing" (TRUCKs), involved the use of inducible cytokine expression to enhance the immune response within the tumor microenvironment [23]. These CAR-T cells were engineered to bypass the immunosuppression of solid tumors by secreting pro-inflammatory cytokines when an antigen is recognized, thus maximizing their potential. The newest, 5th generation CAR-T cells incorporate other signaling pathways, including those from cytokine receptors such as IL-2Rβ, to promote T cell persistence and modulate activation more specifically [24]. The newer designs tackle challenges such as antigen escape, mechanisms of resistance, and toxicity, potentially expanding the reach of CAR-T therapy from blood cancers to solid tumors and autoimmune diseases. Different generations of CARs and development are shown in Fig. 2. The evolution of CAR-T cell therapy: from cancer to autoimmune diseases Chronic diseases like cancer have been recognized as a major concern for years [25]. While standard therapy provides some alleviation, it exhibits substantial drawbacks and detrimental effects on patients' immune systems and general well-being [26]. In recent years, the use of ACT (adoptive cell transfer) in cancer treatment has had a long history [27]. ACT involves extracting a patient’s immune cells, engineering them in a laboratory, and reinfusing them into the body [28]. This therapy boosts the immune system and disease-fighting ability. This method enhances the identification and targeting of cancer cells more effectively Improving treatment outcomes. Among the most effective examples of ACT is CAR-T. CAR-T therapy shows tremendous effects against oncology as a groundbreaking treatment for hematologic malignancies like multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), and diffuse large B-cell lymphoma (DLBCL) [29]. The mechanism behind this success involves the engineered CAR-T cells recognizing specific tumor-associated antigens (TAAs) on cancer cells and destroying the cancer cells through a highly specific immune response [30]. This specificity offers a significant advantage over conventional treatments, as CAR-T cells can persist long-term and adapt to the unique mutations of cancer cells. Of note is that CD19 has been a popular target of CAR-T therapy, with high success rates for B-cell malignancies [31]. Two leading FDA-approved CAR-T treatments targeting CD19 are Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), with very high remission rates among patients with incurable cancers [32]. Similarly, in myeloma, BCMA-targeting CAR-T cells have been shown to be effective, with Abecma and Carvykti being examples of this CAR-T [33]. Since it has successfully cured cancers by targeting the root cause, like overexpressed TAAs, scientists are now exploring CAR-T therapy for autoimmune diseases, where immune systems mistakenly attack their own body tissue, leading to chronic or acute health issues. In this condition, autoreactive cells like β or T cells are ideal targets for CAR-T therapies [34]. Current literature shows that CAR-T cell therapy is being investigated in autoimmune illnesses such as T1D, systemic lupus erythematosus (SLE), and multiple sclerosis (MS) [35]. In autoimmune disease, CAR-T therapy works either by depleting the autoreactive immune cells or restoring immune tolerance. One method is used against pemphigus vulgaris, where chimeric autoantibody receptor (CAAR)-T cells target autoreactive B cells that produce disease-inducing antibodies [36]. Later, another promising approach is CAR-Tregs against T1D and MS, where the primary goal is to restore immune tolerance and suppress the damaging inflammatory response [37]​. The transition to CAR-T therapy for autoimmune diseases is fueled by the fact that it can specifically target and destroy dysfunctional immune cells, providing potential cures rather than merely managing symptoms. Mechanistic insights: how CAR-T cells target pancreatic β-cells in T1D T1D is an autoimmune disease characterized by immune-mediated destruction, especially autoreactive T lymphocytes, leading to immune deficiency and hyperglycemia [38]. The primary etiological factors involve loss of immune tolerance to self-antigens, genetic predisposition, environmental factors, and a dysregulated immune response [39, 40]. Tregs are a specialized subset of T cells that play a crucial role in maintaining immune tolerance and preventing autoimmune disease [41]. The transcription factor FOXP3 and CD25 are highly expressed in Tregs, a subgroup of CD4 + T cells. Treg formation and function are defined by FOXP3, which is regarded as the main regulatory transcription factor. Tregs are identified by their surface markers CD4 and CD25, and their suppressive phenotype and function are coordinated by FOXP3. Tregs express FOXP3, which suppresses immune activation genes to preserve immunological tolerance and controls a number of genes, including CD25 and CTLA-4 [42, 43]. Treg maintains immune tolerance and prevents autoimmune disease by suppressing the activation and proliferation of self-reactive T cells. They do this by producing anti-inflammatory cytokines such as TGF-β, IL-35, and IL-10 [44]. In T1D. However, the Tregs are reduced in number, which will functionally impair them, thereby failing to control pathogenic effector T cells. The breakdown of tolerance is strongly shaped by genetic susceptibility in the human leukocyte antigens HLA region. Recent evidence suggests that HLA contributes a major risk to T1D. HLA-DR3-DQ2 and HLA-DR4-DQ8 are found to be the main cause that predisposes individuals to T1D by presenting β-cell–derived antigens—including insulin, glutamic acid decarboxylase (GAD), and islet antigen-2 (IA-2)—in a way that enhances recognition by autoreactive CD4 + and CD8 + T cells [45–47]. In contrast, HLA-DQ6 and HLA-DR2 promote tolerance by altering antigen presentation. These genetic determinants are further influenced by environmental factors, including viral infections (e.g., enteroviruses), dietary antigens, or environmental toxins, which provide inflammatory stimuli that exacerbate autoreactive T-cell activation in genetically susceptible hosts [48]. Inflammation plays a major role in T1M; once tolerance is broken, autoreactive CD8 + cytotoxic T lymphocytes and CD4 + helper T cells infiltrate pancreatic islets. The inflammatory cytokines FN-γ and IL-1β accelerate β-cell stress and death [49, 50]. Furthermore, programmed cell death pathways that normally limit immune activation are also impaired in T1D, further sustaining autoreactive immune responses [51]. The result is a self-perpetuating cycle of β-cell destruction, loss of insulin production, and chronic hyperglycemia. This integrated pathological cascade—HLA-driven susceptibility, environmental activation, Treg dysfunction, and unchecked autoreactive T-cell expansion—provides the logical foundation for CAR-T therapy in T1D. By genetically reprogramming T cells, CAR-T strategies can intervene at multiple points in this chain. Cytotoxic CAR-T cells may selectively eliminate autoreactive clones, while CAR-Tregs can restore local tolerance through antigen-specific suppression and secretion of anti-inflammatory cytokines. Together, these approaches aim not merely to control blood glucose but to address the root immunological drivers of β-cell loss, thereby offering the potential for durable and disease-modifying therapy (Fig. 3).Fig. 3A brief overview of CAR-T cell therapy in T1D. A Logistics of CAR-T cell therapy: T cells are extracted, genetically engineered with CARs, expanded, and reinfused, (B) Immunopathogenesis of T1D, (C) Therapeutic mechanisms: first, CAR-T cells eliminate autoreactive T cells by killing pathogenic autoreactive T cells; second, target APCs presenting autoantigens, reducing T cell priming; and third, CAR-T cells with regulatory phenotypes produce anti-inflammatory cytokines A brief overview of CAR-T cell therapy in T1D. A Logistics of CAR-T cell therapy: T cells are extracted, genetically engineered with CARs, expanded, and reinfused, (B) Immunopathogenesis of T1D, (C) Therapeutic mechanisms: first, CAR-T cells eliminate autoreactive T cells by killing pathogenic autoreactive T cells; second, target APCs presenting autoantigens, reducing T cell priming; and third, CAR-T cells with regulatory phenotypes produce anti-inflammatory cytokines Recent advancement in CAR T cell therapy for T1D The existing progress of CAR-T cell therapy for diabetes is a significant innovation in clinical science that brings about massive hope of changing diabetes management. The conventional therapies solely deal with addressing the symptoms without offering a definitive cure. The novel strategy is to genetically engineer T cells to selectively target and regulate pathogenic immune cells that are responsible for the autoimmune destruction of pancreatic beta cells. Recent preclinical data have shown auspicious results showcasing the potential of CAR T cells to selectively eliminate autoreactive immune cells, thereby protecting insulin-producing beta cells (Table 1).Table 1Overview of current research efforts on CAR T cell therapy for T1DStudy ObjectiveCAR StructureExperimental Model UsedTargeted AntigensDosageResult OutcomesSummaryAdverse EffectsReferenceInvestigate the prevention of autoimmune diabetes through the adoptive transfer of redirected CD8 T cellsPeptide/b2 microglobulin (b2m)/CD3-zeta chimeric constructNon-obese diabetic (NOD) mice and mouse cell lines• Insulin B chain peptide (InsB15–23)• Islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP206–214)6–10 × 106 cells/mouse (single adoptive transfer)• Efficient killing of autoreactive CD8 T cells (Insulin-reactive and IGRP-reactive) in vitro• Significant reduction in diabetes incidence in NOD mice receiving InsB15–23 redirected T cells• Decreased insulitis in treated miceEfficient killing of autoreactive CD8 T cells; ↓ diabetes incidence; ↓ insulitisNo adverse effects were explicitly reported [52]Investigate if CAR-T cells targeting MHC class II:peptide complexes delay or prevent T1D progressionSingle-chain Fab fragment (scFab) from mAb287 linked to CD28 and CD3ζ domains; third-generation CAR included 4-1BB (CD137) signalling domainNOD mice (young female mice aged 5 weeks)I-Ag7-B:9–23 (R3) peptide complexSingle infusion of 3–5 × 106 CAR-T cells/mouse• Significant delay in onset of diabetes compared to controls• Non treated with 287-CAR mice developed diabetes before 18 weeks of age (vs. 29% in control-CAR and 52% untreated)• Reduced insulin autoantibodies (IAA) in early weeks post-treatment• Selective homing of CAR T cells to pancreatic lymph nodes and persistence up to 2 weeksDelayed diabetes onset; ↓ insulin autoantibodies; homing to pancreatic lymph nodesNo significant adverse effects or changes in general immune cell populations reported [53]Investigate whether Tregs engineered to express CARs targeting peptide:MHC class II complexes regulate autoimmunity in T1DSecond-generation CARs (CD28 and CD3ζ signaling domains) utilizing scFv antibodies from hybridomas (1B2 and FS1 CAR)NOD mouse model, in vitro assays (Tregs, Tconv, BDC2.5 T cells)• Insulin B10-23:I-Ag7 (1B2 CAR)• p63:I-Ag7 (FS1 CAR)Various dosages in vitro (specific cell numbers not detailed in abstract provided)• CAR Tregs proliferated and activated specifically when cultured with antigen-pulsed splenocytes• FS1 CAR Tregs showed enhanced suppression of T cell proliferation compared to polyclonal Tregs• Both 1B2 and FS1 CAR Tregs suppressed cytokine production more effectively than polyclonal Tregs• CAR specificity validated using peptide:I-Ag7 tetramersCAR Tregs proliferated antigen-specifically; FS1 enhanced suppression; ↓ cytokines1B2 CAR conventional T cells (Tconvs), but not FS1 CAR Tconvs, induced Graft-versus-host-disease-like symptoms in NSG mice [54]Investigate insulin-specific CAR-Tregs for treating T1DSecond-generation CAR (CD28 and CD3ζ signaling domains) derived from human insulin-scFvsFemale NOD mice (non-obese diabetic mice)Insulin2.5 × 106 CAR-cTregs injected intravenously into 13-week-old mice• CAR-cTregs were phenotypically stable, expressed regulatory markers (Foxp3, CD25, CTLA-4)• Strong antigen-specific proliferation and suppressive capability in vitro• CAR-cTregs persisted in vivo for up to 17 weeks post-transferStable Foxp3+ CAR-Tregs; antigen-specific suppressionNo adverse effects explicitly reported [55]Develop and evaluate a biomimetic five-module CAR (5MCAR) to target antigen-specific autoimmune CD4 + T cells to treat autoimmune T1DFive-module CAR: composed of pMHCII ectodomain fused with TCR subunits, CD3 signaling modules (γ, δ, ζ), and surrogate coreceptor (CD80-Lck fusion)NOD-SCID mice and NOD mice• pMHCII complexes (RLGL-WE14 peptide:I-Ag7, Insulin B:9–23:I-Ag7, HIP2.5:I-Ag7, HIP6.9:I-Ag7)single infusion (~ 2–5 × 106 cells/mouse)• Rapid killing of autoimmune CD4 + T cells in vitro and in vivo• Significant prevention of diabetes onset in NOD-SCID and spontaneous NOD mouse models• Effective homing and long-term persistence (up to ~ 1 year) in treated mice• Reduction in insulitis and preservation of pancreatic isletsRapid killing of autoreactive CD4+ T cells; diabetes prevention;No significant adverse effects reported [56]Design and evaluate antigen-specific CAR Tregs targeting pancreatic endocrine cells for treating T1DSecond-generation CAR (CD28 and CD3ζ signaling domains) derived from single-chain Fv recognizing human pancreatic endocrine marker (HPi2)Human T cells (in vitro assays with human pancreatic β-cell lines βlox5 and mouse β-cell line NIT-1)HPi2 antigen (human pancreatic endocrine marker)In vitro culture studies (dosage not explicitly detailed)• HPi2-CAR T cells proliferated and activated specifically when co-cultured with human β cells• Increased Granzyme B and LAMP-1 (CD107a) expression in CD8 + T cells• Enhanced IL-2 production in CD4 + T cells co-cultured with human β cells• HPi2 antigen broadly expressed, including CD4 + T cells, causing rapid proliferation collapse due to tonic signallingCAR Tregs proliferated with β cells; ↑ IL-2, Granzyme B; functional collapse due to tonic signalingRapid collapse of CAR T cell expansion due to broad antigen expression causing persistent tonic signaling and functional exhaustion [57]Evaluate the therapeutic potential of insulin B peptide:MHC class II-specific CAR Tregs for preventing autoimmune diabetesSecond-generation CAR (derived from mAb 1B2 scFv, fused to CD28 and CD3ζ signalling domains) specific for insulin B-chain peptide (InsB10-23) presented on IAg7NOD mice (both immunodeficient adoptive-transfer model and spontaneous autoimmune diabetes model)Insulin B-chain (InsB10-23):IAg7 complexSingle infusion of 2.5–3 × 106 CAR-Tregs in spontaneous diabetes model; varying ratios (3:1 or 9:1 Treg: effector T cells) in adoptive transfer model• CAR Tregs effectively proliferated and specifically responded to insulin peptides• Enhanced suppression of effector T cell proliferation, cytokine production, and DC costimulatory molecule expression (CD80/CD86) in vitro• Complete prevention of diabetes in adoptive transfer model at both 3:1 and 9:1 ratios• Significant reduction of spontaneous diabetes incidence (only 43% incidence compared to ~ 80% in controls)• CAR Tregs persisted and exhibited antigen-specific activation markers (PD-1, CTLA-4)Prevented diabetes in transfer model; ↓ incidence in spontaneous model; persistent CAR-TregsNo significant adverse effects reported Table 1Overview of current research efforts on CAR T cell therapy for T1DStudy ObjectiveCAR StructureExperimental Model UsedTargeted AntigensDosageResult OutcomesSummaryAdverse EffectsReferenceInvestigate the prevention of autoimmune diabetes through the adoptive transfer of redirected CD8 T cellsPeptide/b2 microglobulin (b2m)/CD3-zeta chimeric constructNon-obese diabetic (NOD) mice and mouse cell lines• Insulin B chain peptide (InsB15–23)• Islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP206–214)6–10 × 106 cells/mouse (single adoptive transfer)• Efficient killing of autoreactive CD8 T cells (Insulin-reactive and IGRP-reactive) in vitro• Significant reduction in diabetes incidence in NOD mice receiving InsB15–23 redirected T cells• Decreased insulitis in treated miceEfficient killing of autoreactive CD8 T cells; ↓ diabetes incidence; ↓ insulitisNo adverse effects were explicitly reported [52]Investigate if CAR-T cells targeting MHC class II:peptide complexes delay or prevent T1D progressionSingle-chain Fab fragment (scFab) from mAb287 linked to CD28 and CD3ζ domains; third-generation CAR included 4-1BB (CD137) signalling domainNOD mice (young female mice aged 5 weeks)I-Ag7-B:9–23 (R3) peptide complexSingle infusion of 3–5 × 106 CAR-T cells/mouse• Significant delay in onset of diabetes compared to controls• Non treated with 287-CAR mice developed diabetes before 18 weeks of age (vs. 29% in control-CAR and 52% untreated)• Reduced insulin autoantibodies (IAA) in early weeks post-treatment• Selective homing of CAR T cells to pancreatic lymph nodes and persistence up to 2 weeksDelayed diabetes onset; ↓ insulin autoantibodies; homing to pancreatic lymph nodesNo significant adverse effects or changes in general immune cell populations reported [53]Investigate whether Tregs engineered to express CARs targeting peptide:MHC class II complexes regulate autoimmunity in T1DSecond-generation CARs (CD28 and CD3ζ signaling domains) utilizing scFv antibodies from hybridomas (1B2 and FS1 CAR)NOD mouse model, in vitro assays (Tregs, Tconv, BDC2.5 T cells)• Insulin B10-23:I-Ag7 (1B2 CAR)• p63:I-Ag7 (FS1 CAR)Various dosages in vitro (specific cell numbers not detailed in abstract provided)• CAR Tregs proliferated and activated specifically when cultured with antigen-pulsed splenocytes• FS1 CAR Tregs showed enhanced suppression of T cell proliferation compared to polyclonal Tregs• Both 1B2 and FS1 CAR Tregs suppressed cytokine production more effectively than polyclonal Tregs• CAR specificity validated using peptide:I-Ag7 tetramersCAR Tregs proliferated antigen-specifically; FS1 enhanced suppression; ↓ cytokines1B2 CAR conventional T cells (Tconvs), but not FS1 CAR Tconvs, induced Graft-versus-host-disease-like symptoms in NSG mice [54]Investigate insulin-specific CAR-Tregs for treating T1DSecond-generation CAR (CD28 and CD3ζ signaling domains) derived from human insulin-scFvsFemale NOD mice (non-obese diabetic mice)Insulin2.5 × 106 CAR-cTregs injected intravenously into 13-week-old mice• CAR-cTregs were phenotypically stable, expressed regulatory markers (Foxp3, CD25, CTLA-4)• Strong antigen-specific proliferation and suppressive capability in vitro• CAR-cTregs persisted in vivo for up to 17 weeks post-transferStable Foxp3+ CAR-Tregs; antigen-specific suppressionNo adverse effects explicitly reported [55]Develop and evaluate a biomimetic five-module CAR (5MCAR) to target antigen-specific autoimmune CD4 + T cells to treat autoimmune T1DFive-module CAR: composed of pMHCII ectodomain fused with TCR subunits, CD3 signaling modules (γ, δ, ζ), and surrogate coreceptor (CD80-Lck fusion)NOD-SCID mice and NOD mice• pMHCII complexes (RLGL-WE14 peptide:I-Ag7, Insulin B:9–23:I-Ag7, HIP2.5:I-Ag7, HIP6.9:I-Ag7)single infusion (~ 2–5 × 106 cells/mouse)• Rapid killing of autoimmune CD4 + T cells in vitro and in vivo• Significant prevention of diabetes onset in NOD-SCID and spontaneous NOD mouse models• Effective homing and long-term persistence (up to ~ 1 year) in treated mice• Reduction in insulitis and preservation of pancreatic isletsRapid killing of autoreactive CD4+ T cells; diabetes prevention;No significant adverse effects reported [56]Design and evaluate antigen-specific CAR Tregs targeting pancreatic endocrine cells for treating T1DSecond-generation CAR (CD28 and CD3ζ signaling domains) derived from single-chain Fv recognizing human pancreatic endocrine marker (HPi2)Human T cells (in vitro assays with human pancreatic β-cell lines βlox5 and mouse β-cell line NIT-1)HPi2 antigen (human pancreatic endocrine marker)In vitro culture studies (dosage not explicitly detailed)• HPi2-CAR T cells proliferated and activated specifically when co-cultured with human β cells• Increased Granzyme B and LAMP-1 (CD107a) expression in CD8 + T cells• Enhanced IL-2 production in CD4 + T cells co-cultured with human β cells• HPi2 antigen broadly expressed, including CD4 + T cells, causing rapid proliferation collapse due to tonic signallingCAR Tregs proliferated with β cells; ↑ IL-2, Granzyme B; functional collapse due to tonic signalingRapid collapse of CAR T cell expansion due to broad antigen expression causing persistent tonic signaling and functional exhaustion [57]Evaluate the therapeutic potential of insulin B peptide:MHC class II-specific CAR Tregs for preventing autoimmune diabetesSecond-generation CAR (derived from mAb 1B2 scFv, fused to CD28 and CD3ζ signalling domains) specific for insulin B-chain peptide (InsB10-23) presented on IAg7NOD mice (both immunodeficient adoptive-transfer model and spontaneous autoimmune diabetes model)Insulin B-chain (InsB10-23):IAg7 complexSingle infusion of 2.5–3 × 106 CAR-Tregs in spontaneous diabetes model; varying ratios (3:1 or 9:1 Treg: effector T cells) in adoptive transfer model• CAR Tregs effectively proliferated and specifically responded to insulin peptides• Enhanced suppression of effector T cell proliferation, cytokine production, and DC costimulatory molecule expression (CD80/CD86) in vitro• Complete prevention of diabetes in adoptive transfer model at both 3:1 and 9:1 ratios• Significant reduction of spontaneous diabetes incidence (only 43% incidence compared to ~ 80% in controls)• CAR Tregs persisted and exhibited antigen-specific activation markers (PD-1, CTLA-4)Prevented diabetes in transfer model; ↓ incidence in spontaneous model; persistent CAR-TregsNo significant adverse effects reported Overview of current research efforts on CAR T cell therapy for T1D • Insulin B chain peptide (InsB15–23) • Islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP206–214) • Efficient killing of autoreactive CD8 T cells (Insulin-reactive and IGRP-reactive) in vitro • Significant reduction in diabetes incidence in NOD mice receiving InsB15–23 redirected T cells • Decreased insulitis in treated mice • Significant delay in onset of diabetes compared to controls • Non treated with 287-CAR mice developed diabetes before 18 weeks of age (vs. 29% in control-CAR and 52% untreated) • Reduced insulin autoantibodies (IAA) in early weeks post-treatment • Selective homing of CAR T cells to pancreatic lymph nodes and persistence up to 2 weeks • Insulin B10-23:I-Ag7 (1B2 CAR) • p63:I-Ag7 (FS1 CAR) • CAR Tregs proliferated and activated specifically when cultured with antigen-pulsed splenocytes • FS1 CAR Tregs showed enhanced suppression of T cell proliferation compared to polyclonal Tregs • Both 1B2 and FS1 CAR Tregs suppressed cytokine production more effectively than polyclonal Tregs • CAR specificity validated using peptide:I-Ag7 tetramers • CAR-cTregs were phenotypically stable, expressed regulatory markers (Foxp3, CD25, CTLA-4) • Strong antigen-specific proliferation and suppressive capability in vitro • CAR-cTregs persisted in vivo for up to 17 weeks post-transfer • Rapid killing of autoimmune CD4 + T cells in vitro and in vivo • Significant prevention of diabetes onset in NOD-SCID and spontaneous NOD mouse models • Effective homing and long-term persistence (up to ~ 1 year) in treated mice • Reduction in insulitis and preservation of pancreatic islets • HPi2-CAR T cells proliferated and activated specifically when co-cultured with human β cells • Increased Granzyme B and LAMP-1 (CD107a) expression in CD8 + T cells • Enhanced IL-2 production in CD4 + T cells co-cultured with human β cells • HPi2 antigen broadly expressed, including CD4 + T cells, causing rapid proliferation collapse due to tonic signalling • CAR Tregs effectively proliferated and specifically responded to insulin peptides • Enhanced suppression of effector T cell proliferation, cytokine production, and DC costimulatory molecule expression (CD80/CD86) in vitro • Complete prevention of diabetes in adoptive transfer model at both 3:1 and 9:1 ratios • Significant reduction of spontaneous diabetes incidence (only 43% incidence compared to ~ 80% in controls) • CAR Tregs persisted and exhibited antigen-specific activation markers (PD-1, CTLA-4) A study by Sigal Fishman and others in 2016 was on the prevention of T1D via adoptive transfer of mRNA-transfected T cells redirected against diabetogenic CD8 T cells. Here they redirect the specificity of CD8 T cells to target and destroy pathogenic CD8 T cells responsible for auto-destructive destruction of pancreatic islet cells in non-obese diabetic (NOD) mice. Electroporation was utilized to deliver mRNA constructs encoding diabetes-associated autoantigen peptides, such as InsB15–23 and IGRP206–214, linked to β2 microglobulin and CD3-zeta signalling components. Successful targeting and killing of autoreactive CD8 T cells were demonstrated in vitro. At the same time, significant reductions in diabetes incidence and pancreatic lymphocyte infiltration (insulitis) were observed in vivo following the transfer of approximately 6–10 million engineered cells per mouse. At the end of the result, no significant adverse effects were reported [52]. Another study on preventing TIDM by CAR strategy was conducted by Zhang and their team. In this they aim to redirect cytotoxic T cells to target antigen-presenting cells expressing a specific pathogenic MHC class II: peptide complex. For this a monoclonal antibody (mAb287), specific for the insulin B:9–23 peptide bound in register 3 (R3) to the MHC molecule I-Ag7, was used to engineer second- and third-generation CAR constructs. These constructs were transduced into CD8 + T cells isolated from young non-obese diabetic (NOD) mice. CAR-T cells were generated through retroviral transduction. These generated CAR-T cells were transferred into 5-week-old NOD mice at doses ranging from 3 to 5 million cells per animal. The modified T cells were shown to secrete IFN-γ and kill APCs presenting the target complex in vitro, and in vivo they preferentially homed to pancreatic lymph nodes and delayed the onset of hyperglycemia compared to control and untreated mice. As a result, indicated that none of the treated mice developed diabetes by 18 weeks of age, in contrast to 29% in control-CAR-treated and 52% in untreated mice. Additionally, the 287-CAR T cell treatment suppressed early insulin autoantibody formation. During the study, no adverse effect or immune dysregulation was observed [53]. In 2018, Vivian Fung demonstrated that MHC II-specific CARs can effectively regulate autoimmunity in T1D. In this study, second-generation CARs targeting insulin B10-23:I-Ag7 (1B2) and p63:I-Ag7 (FS1) were engineered using monoclonal antibodies. These CARs were retrovirally transduced into Tregs isolated from NOD.FOXP3-GFP mice, using optimized protocols to ensure high transduction efficiency, viability, and purity. To evaluate their function, various assays were performed to assess antigen specificity, cellular activation, proliferation, and suppressive capacity. Both CAR Treg types exhibited antigen-specific activation and demonstrated significantly enhanced suppression of effector T cell responses and pro-inflammatory cytokine production compared to polyclonal Tregs. Importantly, no significant adverse effects were observed during in vitro testing, supporting the potential of CAR Tregs as a targeted and effective immunotherapy for T1D [54]. Insulin-specific CAR Treg strategy is a potential candidate for autoimmune immunotherapy for T1D. Tenspolde and his team construct CAR using scFvs specific to insulin, selected through phage display from human antibody libraries. These were cloned into a second-generation CAR design containing CD28 and CD3ζ signalling domains and further modified to include Foxp3 for stable Treg identity. The engineered cell exhibited a phenotype comparable to natural Tregs and demonstrated strong antigen-specific activation, proliferation, and suppression of effector T cell responses in vitro. However, the engineered cell did not prevent the onset of diabetes in NOD/Ltj mice. The safety dose was found to be 2.5 million per mouse. During the study, no adverse effects or abnormal immune activation were reported [55]. Later, in 2020, a biomimetic five-module chimeric antigen receptor (5MCAR) was constructed to target and deplete antigen-specific CD4 + T cells mediating autoimmune diabetes. The 5MCAR system is a bioengineered chimeric antigen receptor (CAR) that combines CD3 signaling components, peptide–MHC class II (pMHCII) modules, and a surrogate coreceptor made up of CD80 linked to Lck kinase to replicate the natural T cell receptor (TCR) complex. By maintaining the essential biophysical and signaling characteristics of natural TCRs, the design makes it possible to precisely identify clonotypic TCRs expressed on autoreactive CD4 + T cells linked to the pathophysiology of T1D. The 5MCAR cytotoxic T lymphocytes (5MCAR–CTLs) selectively targeted and eliminated pathogenic CD4 + T cells, such as BDC2.5 clones, in experimental models such as NOD and NOD-SCID mice. This prevented the onset of diabetes, stopped insulitis, and removed autoreactive T cells from pancreatic tissue without causing overt toxicity. This method is a novel development in antigen-specific immunotherapy that is in line with new CAR-Treg and pMHC-CAR strategies that modify autoreactive T cell populations in an effort to restore immunological tolerance in T1D. These designed cellular therapies may open the door to long-lasting, tolerance-inducing treatments for autoimmune diabetes by utilizing the power of precise antigen detection in conjunction with customized intracellular signaling to restore immunological homeostasis [56]. Further, Radichev and their team target the pancreatic endocrine marker, i.e., HPi2, with engineered CAR for T1D. In his study the engineered CAR incorporated an anti-HPi2 scFv and was introduced into human T cells via retroviral transduction. Functional assays showed that HPi2-CAR T cells became activated, proliferated, and secreted regulatory cytokines like IL-2, IL-10, and TGF-β when co-cultured with human β cells. In the mouse cell line HPi2 antigen was widely expressed, including on CD4 + T cells, resulting in continuous tonic signaling. This signalling resulted in premature exhaustion and failure of CAR Treg expansion in vitro, particularly in CD4 + CD25 + Tregs. As a result, the research proved that HPi2-CAR was able to functionally activate human T cells, its wide antigen expression and tonic signaling made it inappropriate for T1D immunotherapy [57]. Additionally, a study was conducted to assess the therapeutic potential of CAR-Treg directed against an islet-specific antigen T1D. Here the researcher engineered a CAR from a monoclonal antibody 1B2 that targets the insulin B chain 10–23 peptide presented by the MHC class II molecule IAg7, which is NOD mouse-specific. The engineered T cells showed no loss of regulatory phenotype but exhibited robust antigen-specific activation and suppression in vitro. Their immunosuppressive activity was subsequently confirmed in vivo; when transferred together with diabetogenic BDC2.5 T cells into immunocompromised mice, the InsB-g7 CAR Tregs completely blocked onset of disease and performed better than control Tregs. Furthermore, in NOD mice, a single 2.5–3 million CAR Tregs infusion markedly reduced the incidence of spontaneous diabetes. Mechanistically, the cells inhibited inflammatory reactions by inhibiting effector T cell function, cytokine production, and the expression of co-stimulatory molecules on dendritic cells. The CAR Tregs resided close to islets and pancreatic lymph nodes and increased suppressive markers such as CTLA-4 and PD-1. At the end of the result no side effects were noted, indicating successful early immune modulation. Overcoming the challenges Safety concerns CAR-T cell therapy signifies a revolutionary development in cancer treatment and autoimmune diseases such as T1D. This therapy identifies and eradicates carcinogenic cells by utilizing the body's intrinsic immune response. Beyond its substantial effectiveness, some safety concerns necessitate meticulous assessment and oversight. The critical safety concerns are cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), on/off-target effects, insertional mutagenesis, and malignancies [58]. CRS is a systemic inflammatory response caused by excessive cytokine release, such as interleukin-6 (IL-6), interferon-gamma, and tumor necrosis factor-alpha, into the bloodstream by the immune cells B cells, T cells, macrophages, and natural killer cells. Symptoms can range from mild flu-like signs, such as fever, chills, headache, fatigue, and muscle pain, to severe and potentially life-threatening manifestations, including hypotension, tachycardia, respiratory distress, coagulopathy, and multi-organ dysfunction. Clinical studies have shown that it occurs within days to weeks following CAR-T infusion [59, 60]. ICANS is a severe neurological complication after CAR T-cell therapy, causing confusion, seizures, cerebral edema, and altered consciousness due to immune activation affecting the brain. The exact mechanism remains incompletely understood, though cytokine-mediated inflammation is believed to play a central role. ICANS severity varies significantly; mild cases usually resolve spontaneously, whereas severe cases necessitate urgent medical intervention due to potentially life-threatening complications [61]. In addition to these two hurdles, there's another pressing safety issue to consider: on/off-target effects. These occur when CAR-T cells mistakenly attack healthy tissues expressing antigens similar to those found on tumor cells, leading to unintended tissue damage. For instance, B-cell aplasia is caused by CAR-T cells attacking the CD19 antigen expressed on malignant and normal B cells. Although this may result in reversible immunodeficiency that needs immunoglobulin support, acting against antigens expressed in critical tissue may lead to serious complications, and it thus becomes crucial to use ideal antigen selection solely on the surface of targeted cells [62]. Prolonged safety monitoring is essential for the timely detection of delayed adverse effects, management of chronic problems, and assurance of patient safety over longer durations post-treatment. Although CAR-T cell therapy has dramatically progressed, uncertainties about its long-term safety remain a significant concern. Notably, insertional mutagenesis and secondary malignancies are still important topics in CAR-T cell therapy. Although sophisticated viral vectors employed currently have minimized risks of insertional mutagenesis from those of the previous vectors, gene disruption remains to occur [63]. If insertion occurs close to an oncogene or tumor suppressor gene, this can inadvertently trigger oncogenic pathways or inactivate protective mechanisms, thereby increasing the risk of secondary malignancies. Recent FDA studies highlight these issues, with reports of secondary T-cell malignancies like lymphomas and leukemia within two years post-treatment [64]. Efficacy issues The immunosuppressive microenvironment is one of the biggest impediments to CAR-T cell therapy success in solid tumors [64]. The CAR-T cells, in blood cancer, freely move in the blood, and solid tumors have a complex, suppressive environment around them, which actively contradicts the ecosystem. This condition is typically indicated by hypoxia, deprivation, and oxidative stress and thereby creates adverse conditions for T-cell activity [65]. Besides, tumor cells and stromal cells also secrete multiple factors, including prostaglandin E2, TGF-β, VEGF, and IL-10, that augment myeloid-derived suppressor cell recruitment and activation, regulatory T cell expansion, and tumor-associated macrophage recruitment [66]. These suppressive immune cells suppress CAR-T cell activity directly as well as pre-condition the tumor environment to support tumor growth and immune evasion. Also, the PD-1/PD-L1 axis is yet another important pathway whereby it impairs CAR-T function by modifying the microenvironment [67, 68]. These constraints, combined with manufacturing complexities and variability in patient response, highlight the necessity for continued innovation and optimization of CAR-T cell therapy to maximize its effectiveness on a larger scale. Technical hurdles Significant technical challenges in present CAR-T therapy must be resolved in order to effective clinical use and wider access. The complex manufacturing process is one of the major aspects, such as the consistent and reproducible genetic modification of T cells. Standardized manufacturing is challenging when starting materials from patients vary in immune cell composition and function; variations in immune cell composition and function between individuals can thus affect product consistency. Furthermore, the use of viral vectors for gene transduction is of concern due to issues of efficiency, possible genotoxicity, and general safety [69, 70]. Another important challenge is the rigorous quality control that must be kept throughout the manufacturing process. The highly customized character of these therapies makes maintaining good quality control particularly difficult. Key factors are preserving the viability, purity, potency, and genetic stability of engineered T cells, all of which require accurate, validated analytical techniques and assays. Additionally, the therapeutic efficacy may be impacted by storage and logistical issues, such as cryopreservation and cell product transportation [70]. Scalability of CAR T cell treatments is another ongoing technical difficulty as well. Current manufacturing technologies are costly, resource-intensive, and often insufficient to meet growing clinical demands. Closed-system manufacturing technologies and improved automation are in high demand to facilitate production streamlining, cost reduction, and greater availability [71]. Combination therapies With the therapeutic settings of diabetes evolving, research into combination treatments has also garnered increasing interest, particularly within emerging immunotherapies like CAR T cell therapy. Even though CART cell therapy has already demonstrated revolutionary success in hematologic malignancies, its application to autoimmune disorders like T1D, is in its early stages. Since the etiology of diabetes, particularly T1D is multifactorial with intricate interplays between immune dysregulation, genetic susceptibility, and environmental antigens, a single mode of therapy is improbable for attaining long-term remission or reversal of the disease [72]. This realization underscores the need for a multifaceted treatment approach. CAR T cell therapy is integrated with other pharmacological, cellular, or lifestyle-based interventions to enhance efficacy, reduce potential toxicities, and promote durable immunological tolerance. Combination therapies involving CAR T cells may take several forms. One promising direction involves pairing CAR T cells with agents that modulate the immune environment, such as immune checkpoint inhibitors or cytokine blockers. For instance, the PD-1/PD-L1 axis, acting as an immune checkpoint, can suppress autoreactive T cells and modulate immune activation, making it a promising candidate for synergistic application alongside CAR T cells. Recent preclinical models have demonstrated that enhancing PD-L1 expression—either via mesenchymal stem cell-derived extracellular vesicles or PD-L1-overexpressing platelets—can reduce CD4 + T cell infiltration, promote macrophage phenotype shifts (M1 to M2), and even reverse hyperglycemia in NOD mice. These provide persistence and effectiveness of CAR T cells [73]. Employing immunomodulatory drugs like low-dose IL-2, TGF-β inhibitors, or anti-inflammatory biologics like anti-IL-6 or anti-TNF-α antibodies can potentially reshape the immune landscape, decrease systemic inflammation, and facilitate the survival and functionality of therapeutic CAR T cells [74]. Further, there exists promise in synergizing CAR T cell therapy with other cell-based therapies, including Treg therapies. Engineered Tregs, infused separately or co-engineered to co-express CARs directed against islet antigens, could potentially cooperate with CAR T cells to dampen pathologic immune responses without impairing normal immune surveillance. The two-cell strategy might exploit the cytotoxicity of CAR T cells against autoreactive clones and the regulatory activities of Tregs to foster long-term immune tolerance [75]. Monoclonal antibodies are another well-established immunomodulatory method that can be synergistically combined with CAR-based treatments [76]. Agents such as teplizumab (anti-CD3 monoclonal antibody) have already demonstrated clinical utility by retarding the development of stage 3 T1D in high-risk patients [77]. Teplizumab, in a landmark trial, retarded insulin dependence for approximately three years, reduced pro-inflammatory cytokines (e.g., TNF-α and IFN-γ), and induced T cell exhaustion—an effect potentially therapeutic in T1D. Although monoclonal antibodies have thus far been applied in non-antigen-specific settings, future integration with CAR T cells or CAR T-regs may provide an impressive dual mechanism of both slowing disease advancement and facilitating immune regulation [78, 79]. Another direction of investigation is the co-administration of CAR T cells with antigen-specific tolerizing therapies. These include peptide-based vaccines, tolerogenic dendritic cells, or nanoparticles carrying β-cell antigens. These interventions seek to re-educate the immune system to re-establish tolerance to pancreatic β-cells. For example, pairing CAR T cells with a proinsulin peptide vaccine could allow for more site-specific deletion or modulation of autoreactive T cell clones, leaving residual β-cell mass intact and boosting endogenous insulin production [80]. Furthermore, regenerative medicine approaches can be synergistically combined with CAR T therapy. The simultaneous administration of stem cell-derived islet transplantation or β-cell regeneration inducers may provide a twofold benefit, eradicating the autoimmune attack through CAR T cells while reconstituting the lost β-cell pool in tandem. Yet, if these strategies are to be successful, CAR T cells need to suppress the immune assault but remain not only blind to the recently infused or regenerating β-cells. That will require strongly specific CAR design and strict control of CAR T cell function, potentially through use of inducible systems or temporary CAR presentation with mRNA technology [6, 81]. Metabolic and lifestyle-based interventions also present opportunities as additions to CAR T cell therapy. For example, dietary changes, modulation of the gut microbiome, and exercise routines have been found to modulate systemic inflammation and immune function. The incorporation of these non-pharmacological interventions could increase the effectiveness of CAR T cell therapy by providing a better systemic setting. In addition, simultaneous glycemic management with current treatments such as insulin shots or SGLT2 inhibitors may be required in the initial stages following CAR T infusion to ensure metabolic stability until immune equilibrium is re-established [82]. In summary, combination therapies are a critical horizon for clinical translation of CAR T cell therapy for diabetes. The combination of CAR T cells with immunomodulators, antigen-specific tolerance methodologies, regenerative medicine, and metabolic therapies has the potential for more efficacious, safe, and sustained results. Yet, intense preclinical testing and clinically relevant trials are needed to identify the best combinations, dosing regimens, and safety profiles prior to broad use. Future directions: engineering CAR-T cells for personalized diabetes treatment Overcoming current limitations and employing cutting-edge engineering techniques to develop customized, targeted, and long-term therapies are key to the future of CAR-T cell therapy in T1D. Scientists are revolutionizing the way they think about CAR-T cells, considering them a multipurpose tool to treat autoimmune diseases, modulate immune system responses, and restore pancreatic β-cell function in the wake of cancer cure success. Nevertheless, CAR-T therapy will transition from a theoretical model to a practical aid in T1D treatment within the next decade. Securing long-term safety in children, optimizing production for global availability, and employing artificial intelligence to forecast the optimal CAR configuration are milestones. With advancements in synthetic biology and CRISPR-based editing technology, the concept of "living drugs" capable of dynamically controlling autoimmune flares becomes increasingly possible [83]. Once deemed impossible in T1D therapy, CAR-T therapies offer not only glucose management but also sustained remission through immune modulation and β-cell regeneration equilibrium. Improving safety and specificity with innovative CAR designs The efficacy of existing CAR-T therapies for T1D needs to be weighed against the risk of off-target effects. Logic-gated CAR systems requiring dual antigen recognition for activation are being designed as a solution to this issue. To selectively kill pathogenic T cells in pancreatic islets, for instance, Harvard scientists engineered a "5-module CAR" (5MCAR) that mimics normal T cell receptor complexes [6]. In mouse models, 5MCAR T cells eliminated autoreactive CD8 + T cells while sparing non-pathogenic immune cells, preventing diabetes onset with no observed toxicity. Similarly, AND-gate CARs that activate only when both CD3 (T cell marker) and β-cell antigens (e.g., preproinsulin) are detected could minimize collateral damage. Complementary safety mechanisms like inducible caspase-9 (iC9) suicide switches enable doctors to switch off CAR-T cells with small drugs if toxic effects arise. These modifications try to cause localized immunosuppression without systemic compromise [56]. Regulatory T cell engineering (CAR-Tregs): restoring immune tolerance Utilizing CARS to produce Tregs to suppress autoimmune attacks is a new approach. CAR-Tregs will be designed to express receptors for β-cell-specific antigens, such as GAD65 or IA-2, in the pancreatic islets and secrete anti-inflammatory cytokines such as TGF-β and IL-10. Initial studies demonstrate that CAR-Tregs maintain β-cell mass and reduce insulitis by over 60% in NOD mice versus controls. Long-term survival remains problematic, however [84]. Among the methods being considered are:I.Epigenetic adjustments to stabilize Treg-specific demethylated regions (TSDRs) [85].II.Cytokine support combinations to improve survival, such as IL-2/IL-33 [86].III.FOXP3 enhancers modified by CRISPR to strengthen Treg identity 37IV.Scaled manufacturing procedures are being evaluated in early-phase studies, such as the CAR-Treg research supported by Diabetes Australia, while keeping an eye out for any unexpected plasticity into effector T cells [85]. I.Epigenetic adjustments to stabilize Treg-specific demethylated regions (TSDRs) [85]. Epigenetic adjustments to stabilize Treg-specific demethylated regions (TSDRs) [85]. II.Cytokine support combinations to improve survival, such as IL-2/IL-33 [86]. Cytokine support combinations to improve survival, such as IL-2/IL-33 [86]. III.FOXP3 enhancers modified by CRISPR to strengthen Treg identity 37 FOXP3 enhancers modified by CRISPR to strengthen Treg identity 37 IV.Scaled manufacturing procedures are being evaluated in early-phase studies, such as the CAR-Treg research supported by Diabetes Australia, while keeping an eye out for any unexpected plasticity into effector T cells [85]. Scaled manufacturing procedures are being evaluated in early-phase studies, such as the CAR-Treg research supported by Diabetes Australia, while keeping an eye out for any unexpected plasticity into effector T cells [85]. Antigen-specific targeting of autoreactive T cell clones Single-cell sequencing may soon be used in personalized CAR-T treatments to find autoreactive TCRs unique to each patient. By cloning TCRs from islet-infiltrating T cells and creating CARs that can identify peptide-MHC complexes specific to pathogenic clones, the Kent and Brehm laboratories invented this strategy [87]. These CAR-T cells spared unrelated lymphocytes while eliminating over 90% of target T cells in humanized mouse models. Bispecific CARs that activate both TCRs and co-stimulatory molecules (such as CD28) to increase targeting fidelity are the subject of parallel research. In the future, such precision may take the role of general immunosuppressants, providing remission without raising the risk of infection [6]. Synergistic approaches: combining CAR-T cells with β-cell regeneration New combinatorial approaches seek to combine β-cell restoration and CAR-T therapy:I.CAR-T cells with β-cells generated from stem cells: Implanting stem cell-derived islets encased in immune-shielding biomaterials is made possible by autoreactive T cell clearance.II.Trophic factors plus CAR-T cells: After treatment, GLP-1 or betatrophin analogs are given to promote the growth of endogenous β-cells.III.CAR-Tregs + antigen-specific vaccination: By distributing epitopes, low-dose autoantigen vaccines (such as proinsulin peptides) may increase CAR-Treg activity.IV.This paradigm is demonstrated by the current experiment at the Royal Adelaide Hospital, which is investigating β-cell regeneration adjuvants while delaying the development of T1D utilizing CAR-T cells [88]. I.CAR-T cells with β-cells generated from stem cells: Implanting stem cell-derived islets encased in immune-shielding biomaterials is made possible by autoreactive T cell clearance. CAR-T cells with β-cells generated from stem cells: Implanting stem cell-derived islets encased in immune-shielding biomaterials is made possible by autoreactive T cell clearance. II.Trophic factors plus CAR-T cells: After treatment, GLP-1 or betatrophin analogs are given to promote the growth of endogenous β-cells. Trophic factors plus CAR-T cells: After treatment, GLP-1 or betatrophin analogs are given to promote the growth of endogenous β-cells. III.CAR-Tregs + antigen-specific vaccination: By distributing epitopes, low-dose autoantigen vaccines (such as proinsulin peptides) may increase CAR-Treg activity. CAR-Tregs + antigen-specific vaccination: By distributing epitopes, low-dose autoantigen vaccines (such as proinsulin peptides) may increase CAR-Treg activity. IV.This paradigm is demonstrated by the current experiment at the Royal Adelaide Hospital, which is investigating β-cell regeneration adjuvants while delaying the development of T1D utilizing CAR-T cells [88]. This paradigm is demonstrated by the current experiment at the Royal Adelaide Hospital, which is investigating β-cell regeneration adjuvants while delaying the development of T1D utilizing CAR-T cells [88]. Addressing disease heterogeneity through adaptive platforms The various causes of T1D, ranging from genetic predispositions to environmental triggers, necessitate flexible CAR-T systems. Clinicians can retarget therapies as autoimmune epitopes change thanks to modular platforms with swappable antigen-binding domains; for instance, a CAR-T cell originally programmed against GAD65 could be re-engineered to target ZnT8 if new autoantibodies emerge. Dynamic dose adjustments are made possible by real-time monitoring using circulating β-cell DNA or TCR repertoire sequencing, as demonstrated in NIH-funded studies. This flexibility is essential because of the varying rates of progression seen across age groups and HLA haplotypes as well [6]. Scaling manufacturing for broad accessibility Among the innovations to democratize access are:I.Automated closed-system bioreactors: Platforms such as the Miltenyi Prodigy® eliminate manual handling and improve batch consistency for CAR-Treg expansions;II.Viral-free gene editing: Transposon systems (e.g., Sleeping Beauty) lower production costs compared to lentiviral vectors; Allogeneic "off-the-shelf" CAR-Tregs: CRISPR-edited to delete HLA class II and incorporate safety switches, these cells resist host rejection while allowing controlled persistence [89, 90]. I.Automated closed-system bioreactors: Platforms such as the Miltenyi Prodigy® eliminate manual handling and improve batch consistency for CAR-Treg expansions; Automated closed-system bioreactors: Platforms such as the Miltenyi Prodigy® eliminate manual handling and improve batch consistency for CAR-Treg expansions; II.Viral-free gene editing: Transposon systems (e.g., Sleeping Beauty) lower production costs compared to lentiviral vectors; Allogeneic "off-the-shelf" CAR-Tregs: CRISPR-edited to delete HLA class II and incorporate safety switches, these cells resist host rejection while allowing controlled persistence [89, 90]. Viral-free gene editing: Transposon systems (e.g., Sleeping Beauty) lower production costs compared to lentiviral vectors; Allogeneic "off-the-shelf" CAR-Tregs: CRISPR-edited to delete HLA class II and incorporate safety switches, these cells resist host rejection while allowing controlled persistence [89, 90]. Expanding to other autoimmune conditions Teachings from T1D Treatments for linked disorders are being informed by CAR-T trials:I.Multiple sclerosis: B cells that produce myelin autoantibodies are depleted by CD19-directed CAR-T cells.II.Synovium-targeted CAR-Tregs reduce joint inflammation in rheumatoid arthritis.III.Transplant rejection: Alloantigen-specific CAR-T cells establish tolerance to donor organs [91, 92]. I.Multiple sclerosis: B cells that produce myelin autoantibodies are depleted by CD19-directed CAR-T cells. Multiple sclerosis: B cells that produce myelin autoantibodies are depleted by CD19-directed CAR-T cells. II.Synovium-targeted CAR-Tregs reduce joint inflammation in rheumatoid arthritis. Synovium-targeted CAR-Tregs reduce joint inflammation in rheumatoid arthritis. III.Transplant rejection: Alloantigen-specific CAR-T cells establish tolerance to donor organs [91, 92]. Transplant rejection: Alloantigen-specific CAR-T cells establish tolerance to donor organs [91, 92]. Conclusions and future perspectives While early successes in preclinical models demonstrate remarkable precision in eliminating autoreactive T cells and preserving β-cell function, the journey from bench to bedside remains fraught with challenges that require multidisciplinary collaboration. Important advancements like β-cell-specific CAR-Tregs have shown > 60% preservation of islet mass in murine models by locally suppressing inflammation without systemic immunosuppression, while novel engineering approaches like the 5-module CAR (5MCAR) system have achieved targeted depletion of pathogenic CD4 + T cells in diabetic mice with unprecedented specificity. The investigation of CAR-T cell therapy in diabetes represents a pivotal convergence of oncology innovation and autoimmune disease treatment, offering transformative potential to shift from lifelong symptom management to curative strategies. The research must, however, balance the conflict between therapeutic efficacy and safety, especially in light of new information from cancer studies that suggests CAR-T cells might seldom paradoxically cause autoimmune reactions. The upcoming decade will be characterized by three crucial frontiers: Personalization: Using single-cell TCR sequencing to target distinct autoimmune repertoires, treatments may be developed for each patient. Scalability: Using automated bioreactor systems and CRISPR-edited allogeneic CAR-Tregs to overcome the constraints of autologous treatment. Integrating CAR-T cells with closed-loop biomarker monitoring and β-cell regeneration technology is known as system integration. This paradigm's eventual success will hinge on applying the knowledge gained from CD19 CAR-T studies, which show that B-cell reconstitution patterns are associated with long-lasting remission, to diabetes-specific issues, including disease heterogeneity and the complexity of the pancreatic microenvironment. The science is at a crossroads between cautious optimism and the sobering reality of immune engineering's limits as phase I trials with CAR-Tregs begin. By utilizing artificial intelligence to optimize CAR design and establishing interdisciplinary collaborations among diabetologists, synthetic biologists, and computational immunologists, this treatment could eventually live up to its potential as a means of immune resetting and long-lasting β-cell recovery. In order to guarantee that diabetes becomes the next frontier that cellular immunotherapy conquers, the future requires equal amounts of scientific chutzpah and careful safety validation.